Bøger i Cancer Treatment and Research serien

The other perspec tive driving the neoadjuvant approach is an emerging awareness that for most solid tumor systems, neoadjuvant treatment responses can facilitate less muti lating surgery with comparable levels of local disease control.

It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up-to-date, easily available on a single library shelf or by a single personal subscription.

Mammary Tumor Cell Cycle, Differentiation and Metastasis is the fifth volume since 1988 in a series designed to broadly examine current advances in the cellular and molecular biology of breast cancer.

The decade of the 1990s will see an increasing emphasis on the modulation of chemotherapeutic drug selectivity and in the 'lock and key' approach to new targets to control malignant proliferation. The contents of this volume appropriately reflect these scientific undercurrents. An emerging powerful tool of molecular pharmacology is described by Holcenberg and Wu. Manipulation of genetic expression by modification of messenger RNA is now within our reach, and the basic concepts are suc­ cinctly reviewed as a primer on future biochemical engineering of new anti­ cancer molecules. Another concept that appears to be worthy of further study in both experimental and clinical chemotherapy concerns obs'ervations on the modulation of activity by the nucleoside transport inhibitor, dipyri­ damole. How potentiation of several anticancer drugs occurs has practical, as well as theoretical, ramifications, discussed by Goel and HowelL Finally, O'Dwyer and La Creta present a fresh look at sensitization of chemotherapy by the hypoxic radiosensitizer, SR-2731.

It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription.

Attempts to harness the inherent complexity of MDS by devising `classifications' which group the various syndromes as one disease is as misguided as saying that a pneumonia is not infectious because it did not respond to antibiotics.

It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription.

Furthermore, in many developing countries lung cancer is now being diagnosed with increasing frequency in both sexes and it is expected to be a major cause of death in those countries later in this century or the beginning of next century if the tobacco consumption will continue its rapid rise.

How ever, much can be done for these patients - resection of primary cancers, omentectomies to reduce ascites formation, management of recurrent ascites, management of intestinal obstruction, nutritional care, and, hopefully, intraperitoneal chemotherapy.

Recent Advances in Clinical Trial Design and Analysis brings together biostatisticians doing cutting-edge research and explains some of the more recent developments in biostatistics to clinicians and scientists who work in clinical trials.

The clinical role for other new treatments has not yet been clearly defined, although exciting preliminary data from recent clinical trials are now available. ' Chapters 4, 5, and 6 review the rationale and clinical use of the compounds known collec tively as the aromatase inhibitors, which can also be used to suppress sex steroid hormone levels.

It was not too many years ago that the role of chemotherapy for head and neck cancer consisted of single-agent methotrexate for selected patients with recurrent disease. When oncologists began testing chemotherapy in the combined modality approach, trials consisted of induction chemotherapy and use of single agents as radiosensitizers.

Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/or expand the graft.

Offers an overview of topics related to cancer chemoprevention. This book provides a review of topics ranging from basic research arenas to clinical trial design, implementation, and interpretation. It covers areas necessary for understanding the field of cancer chemoprevention for the interested reader, for individuals wishing to enter this area.

The topical areas include active areas of the application of biostatistics to modern cancer research: survival analysis, screening, diagnostics, spatial analysis and the analysis of microarray data. Biostatistics is an essential component of basic and clinical cancer research.

Peter Angelos Numerous ethical issues arise in the care of oncology patients. Although much has been written in the last several decades on ethical issues in caring for patients, few volumes have sought to focus the exploration on ethical issues particularly relevant to the care of cancer patients.

This book examines the issues surrounding the increase in skin cancers as a consequence of the lowered cellular immunoresponse in transplant patients. The rise in incidence of this cancer seems to parallel the overall increase in their long-term survival rate.

During a particular session there was a presentation on the use of peripheral blood as the sole source of stem cells for transplantation, and a member of the audience rose to state that it was medically unethical to consider such treatment, as it certainly could not contain stem cells.

This volume highlights research issues specific to geriatric oncology in the field of carcinogenesis and cancer prevention and treatment, based on the biologic interactions of cancer and age. It conveys a sustainable way of thinking about cancer and aging.

A review of state-of-the-art therapies currently used with leptomeningeal cancer patients, including information on symptom management, new clinical trials, epidemiology, as well as research in animal models for experimental treatments.

Liver-Directed Therapy for Primary and Metastatic Liver Tumors is a comprehensive examination of tumors of the liver. Because of the unique and comprehensive examination of liver tumors, this work is an excellent resource for surgical, transplant and medical oncologists, surgeons, gastroenterologists, and radiologists.

Gastrointestinal tract malignancies encompass a spectrum of diseases with marked differences in etiology, incidence, biological behavior, and treatment outcome.

One of the most exciting areas of cancer research now is the development of agents which can target signal transduction pathways that are activated inappropriately in malignant cells.

- Volume is divided into four sections, allowing easy navagation for researchers and practicing physicians- Text includes clinical trials- Written by leaders in the field

Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.

Ovarian carcinoma continues to be responsible for more deaths than all other gynecologic malignancies combined, due to a continued inability to achieve detection of early (rather than advanced) stage disease and the lack of effective tumor-specific therapeutics.

The first book to cover both basic science and clinical research, providing a comprehensive review of the current knowledge on cytokines and cancer. Written by leading figures in the field of cytokine biology and cytokine therapeutics.

Leukemia is a malignant disease which continues to play a cutting edge role in the discovery of basic knowledge about the malignant process and about the potential for controlling these malignant diseases. This title covers such topics as chromosome 16, chromosome 5, the BCL-2 gene, 11q23 breakpoint leukemias, and hematopoietic stem cells.

Resistance to treatment represents the final common outcome for far too many patients with cancer. In this volume of Drug Resistance, leading investigators in the field have reviewed the most basic mechanisms of drug resistance, and have proposed ways to modulate resistance.